Newsroom
Strive to Deliver Breakthroughs
-
June 16, 2021
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment
Cambridge, MA, Rotterdam, NL, Suzhou CN – June 16, 2021 Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-y...
View more -
June 08, 2021
HabourBioMed will announce a bispecific antibody at Antibody Engineering & Therapeutics Conference
HabourBioMed will announce a bispecific antibody at Antibody Engineering & Therapeutics （AET）Conference (June 8-10, 2021). This anti...
View more -
June 02, 2021
Capital Group increased its stake in Harbour BioMed to 6.1%
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands - June 2, 2021 According to public information, on May 31, the C...
View more -
May 11, 2021
Harbour BioMed Announces Dosing of First Patient in Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands - May 11, 2021 Harbour BioMed (“HBM”, HKEX: ...
View more -
April 13, 2021
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands - April 13, 2021 Harbour BioMed ("HBM"; ...
View more -
March 30, 2021
Harbour BioMed Reports Full Year 2020 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., SUZHOU, China, Rotterdam, Netherlands - March 30, 2021 HBM Holdings Limited (“Harbour BioMed”, “HBM” or ...
View more -
March 23, 2021
Harbour BioMed Appoints Mai-Jing Liao, PhD, as Chief Commercial Officer
Since its establishment, Harbour BioMed (HBM) continues to grow leaps and bounds with its innovative technology and differentiated R&D pipeline that keeps ...
View more -
March 22, 2021
Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China
Cambridge, MA, Rotterdam, NL, Shanghai, CN, Suzhou, CN – March 22, 2021 Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the...
View more -
March 12, 2021
Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial
Cambridge, MA, Rotterdam, NL, Shanghai, CN, Suzhou, CN – March 12, 2021 Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the...
View more -
February 26, 2021
Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors
Cambridge, MA, Rotterdam, NL, Suzhou, CN – February 26, 2021. Harbour BioMed (HBM) (HKEX:02142) today announced that the China National...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1